Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
latest_posts
- 1
Revealing the Specialty of Food Matching: Improving Culinary Encounters - 2Israeli president concerned over proposed renaming of park
- 3The most effective method to Look at Medical caretaker Compensations Across Various Clinics
- 4Astronomers detect rare 'free floating' exoplanet 10,000 light-years from Earth
- 5Worldwide Objections Ideal For A Golf Outing
- Trump says Cuba is 'ready to fall' after capture of Venezuela's Maduro
- Australians told to continue Easter travel plans despite fuel shortages
- Doctors seek to understand why quitting antidepressants causes withdrawal for some
- NASA releases stunning first images of Earth taken by the Artemis II astronauts
- Watch Chinese astronauts enjoy '1st ever space BBQ' from Tiangong's brand-new oven (video)
- Images of Bangladeshi motorcyclists sleeping at petrol pumps are AI-generated
- ‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- Vote In favor of Your Favored Web-based Venture Stage
- Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer
